Views & Analysis | Perspectives on pharma industry issues

R&D

Net Treatment Benefit in rare disease trials: Aligning trial...

Net Treatment Benefit provides a formal framework to integrate multiple prioritised outcomes into a single measure of overall treatment effect.

R&D

How innovative trial approaches are advancing rare disease r...

Innovative trial designs that harness data augmentation, RWD, and the power of AI are enabling a new era of rare disease research.

Market Access

What rare disease commercialisation in Europe teaches us - a...

Rare disease launches are the ultimate stress test for European commercialisation.

R&D

Agentic AI and the human element: Building trustworthy autom...

The future of clinical trials isn’t about replacing people. It’s about empowering them with smarter tools.

Oncology

Sponsored

Collaboration & personalisation in rare disease R&D, with AO...

For Rare Disease Day, in an AOP Health-sponsored podcast Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, discussed their work.

Oncology

Sponsored

Planting seeds of success: A new early-stage fund in Cancer ...

Debiopharm Innovation Fund, the Swiss biopharma’s strategic investing arm managing a $150 million fund, is looking to get involved earlier in the investment process with the launch of a new

Patients

The NHS risk crisis: The failure of risk in a complex health...

*Disclaimer: The views and opinions expressed here are the author’s own and do not necessarily reflect those of pharmaphorum or its editorial staff.

Digital

DTx East: Day 2

Tuesday’s packed schedule will let attendees hear from Anders Tveteraas, international head of patient solutions and services at Novartis and Julie Anderson, principal, behavioural health s

Sales & Marketing

virtual electronic medical record interface

Sponsored

5 forces reshaping pharma commercialisation in 2026

As infrastructure bottlenecks ease and regulatory frameworks mature, pharma's AI adoption is shifting from proof-of-concept to production-grade deployment

Sales & Marketing

Swiss train speeding across bridge against landscape background

A fast start to 2026 signals continued investor confidence i...

Key factors in Switzerland’s success that could make other European life sciences hubs more attractive to investors.

Digital

AI scientists and the robotic labs of tomorrow

AI scientists will no longer operate at the margins of life sciences research - they'll become essential collaborators in the labs of tomorrow.

Digital

On digital health and the Rural Health Transformation Progra...

As reported in January this year, the United States Centers for Medicare & Medicaid Services (CMS) rolled out $10 billion in

Market Access

What rare disease commercialisation in Europe teaches us - a...

Rare disease launches are the ultimate stress test for European commercialisation.

Market Access

Biotech leaders: ‘They're shoving this industry into the arm...

At the Biotech Showcase during JPM Week, biotech leaders expressed frustration at the US's lack of concern about Chinese biotech progress.

Oncology

Sponsored

Collaboration & personalisation in rare disease R&D, with AO...

For Rare Disease Day, in an AOP Health-sponsored podcast Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, discussed their work.

Oncology